In a regulatory filing, Zydus Cadila said it has received approval from the DCGI to start the phase 3 clinical trials in COVID-19 patients with its biological therapy Pegylated Interferon alpha-2b or PegiHep.
from Top Business News- News18.com https://ift.tt/3g8RhIn
0 comments: